MX2023004633A - Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. - Google Patents
Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.Info
- Publication number
- MX2023004633A MX2023004633A MX2023004633A MX2023004633A MX2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A
- Authority
- MX
- Mexico
- Prior art keywords
- btla
- modulators
- same
- lymphocyte attenuator
- binding agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105067P | 2020-10-23 | 2020-10-23 | |
| US202163192984P | 2021-05-25 | 2021-05-25 | |
| PCT/US2021/056289 WO2022087441A2 (en) | 2020-10-23 | 2021-10-22 | B and t lymphocyte attenuator (btla) modulators and method of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004633A true MX2023004633A (es) | 2023-05-12 |
Family
ID=78695822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004633A MX2023004633A (es) | 2020-10-23 | 2021-10-22 | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391872A1 (enExample) |
| EP (1) | EP4232480A2 (enExample) |
| JP (1) | JP2023546713A (enExample) |
| KR (1) | KR20230096024A (enExample) |
| AU (1) | AU2021365611A1 (enExample) |
| CA (1) | CA3196493A1 (enExample) |
| IL (1) | IL302135A (enExample) |
| MX (1) | MX2023004633A (enExample) |
| WO (1) | WO2022087441A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023259623A1 (en) * | 2022-04-27 | 2024-11-21 | First Tracks Biotherapeutics, Inc. | B and t lymphocyte attenuator (btla) modulators and method of using same |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2007001459A2 (en) * | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| CA2769473A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| JOP20190261A1 (ar) * | 2017-05-19 | 2019-11-05 | Lilly Co Eli | أجسام مضادة لعامل مساعد لـ btla واستخداماتها |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CN114585416B (zh) * | 2019-04-01 | 2025-01-17 | 莱克制药股份有限公司 | 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 |
| AU2023259623A1 (en) * | 2022-04-27 | 2024-11-21 | First Tracks Biotherapeutics, Inc. | B and t lymphocyte attenuator (btla) modulators and method of using same |
-
2021
- 2021-10-22 MX MX2023004633A patent/MX2023004633A/es unknown
- 2021-10-22 AU AU2021365611A patent/AU2021365611A1/en active Pending
- 2021-10-22 JP JP2023524833A patent/JP2023546713A/ja active Pending
- 2021-10-22 IL IL302135A patent/IL302135A/en unknown
- 2021-10-22 CA CA3196493A patent/CA3196493A1/en active Pending
- 2021-10-22 US US18/250,194 patent/US20230391872A1/en active Pending
- 2021-10-22 KR KR1020237017524A patent/KR20230096024A/ko active Pending
- 2021-10-22 EP EP21810816.5A patent/EP4232480A2/en active Pending
- 2021-10-22 WO PCT/US2021/056289 patent/WO2022087441A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022087441A3 (en) | 2022-08-25 |
| CA3196493A1 (en) | 2022-04-28 |
| JP2023546713A (ja) | 2023-11-07 |
| AU2021365611A9 (en) | 2025-03-13 |
| EP4232480A2 (en) | 2023-08-30 |
| AU2021365611A1 (en) | 2023-06-08 |
| KR20230096024A (ko) | 2023-06-29 |
| US20230391872A1 (en) | 2023-12-07 |
| IL302135A (en) | 2023-06-01 |
| WO2022087441A2 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002586A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
| CO2021004534A2 (es) | Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral | |
| ECSP21090414A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| BR112021024507A2 (pt) | Agonista de pd-1 e método de uso do mesmo | |
| CL2021001993A1 (es) | Inhibidores específicos del complejo de ltbp de tgfß y usos de los mismos. | |
| MX2020014158A (es) | Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos. | |
| MX391028B (es) | Anticuerpos que se unen a cd39 y sus usos | |
| MX2020011580A (es) | Componentes de andamio, sistema y metodo. | |
| PE20211867A1 (es) | Anticuerpos biespecificos y su uso | |
| AR111752A1 (es) | Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos | |
| AR117565A1 (es) | Agentes de unión a c3 y método de uso de los mismos | |
| MX2017009904A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
| MX2020004561A (es) | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. | |
| MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
| MX2019004667A (es) | Plataforma de funcion como servicio (faas) en redes de cadena de bloques. | |
| CO2022004743A2 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| MX2024001595A (es) | Anticuerpos btla. | |
| MX2024013146A (es) | Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| MX2018011262A (es) | Metodo de comunicacion de dispositivo a dispositivo (d2d) y dispositivo de d2d. | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| CO2020003165A2 (es) | Anticuerpos de la proteína de muerte celular programada 1 | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. |